Freeze-and-Immune combo takes on tough liver cancer

NCT ID NCT06710223

Ongoing Disease control Sponsor: University of California, San Diego Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 29, 2026 · Updated 3 times

Summary

This early-phase trial tests a new approach for people with advanced liver cancer that cannot be removed by surgery. Doctors will freeze part of the tumor (cryoablation) and deliver an immune-boosting drug directly into the liver's blood supply. After that, participants receive two immunotherapy drugs every four weeks. The main goal is to see if this combination is safe and tolerable.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SD-101 (nelitolimod), durvalumab, tremelimumab, and cryoablation
What this could lead to: If successful, this could point toward a new combination treatment that helps control advanced liver cancer.
What could go wrong: This is a very early phase 1 trial with only 20 people, so it is primarily checking safety. The treatment may not shrink tumors or improve survival, and side effects could be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA

Contacts and locations

Locations

University of California, San Diego

San Diego, California, 92093, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.